Shot in the arm for GSK as the EU approves its endometrial cancer treatment Jemperli
Breakthrough: GSK boss Emma Walmsley (pictured) has pushed to boost the company's drug pipeline
GSK has scored another win for its drug pipeline. European watchdogs have given a cancer treatment developed by the pharmaceutical giant the thumbs up.
Jemperli has been approved by the European Commission for use in addition to chemotherapy to treat endometrial cancer, which affects the uterus.
EU regulators have also greenlit Jemperli for use on its own or after chemotherapy. It follows similar approvals for the drug in the US.
GSK head of oncology research Hesham Abdullah said: 'With this approval we can expand the number of patients who could potentially benefit from treatment with Jemperli in Europe.'
The drug giant has invested heavily in Jemperli and wants to expand its use to different types of cancer.
Last month, the company's blood cancer drug Blenrep achieved a major goal in a late-stage clinical trial after a series of setbacks.
GSK boss Emma Walmsley has pushed to boost the company's drug pipeline after it spun off its consumer health business Haleon last year.
The strategy appears to be working: GSK has raised its profit forecasts for the second time this year after strong sales of its Arexvy vaccine, which protects against respiratory syncytial virus (RSV).